Side-by-side · Research reference
MazdutidevsPTD-DBM
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 3HUMAN-REVIEWED19/62 cited
BAnimal-StrongHUMAN-REVIEWED10/40 cited
Mazdutide
GLP-1/Glucagon Dual Agonist · Oxyntomodulin Analogue · Phase 3
SQ · Abdomen · Once WeeklyJi 2026
01Mechanism of Action
Parameter
Mazdutide
PTD-DBM
Primary target
GLP-1 receptor and glucagon receptorAbdul 2026Elmendorf 2026
CXXC5–Dishevelled protein-protein interaction
Pathway
Dual agonism: GLP-1R → satiety, insulin secretion, gastric emptying delay; GCGR → hepatic lipolysis, energy expenditure, thermogenesisElmendorf 2026Abulehia 2026
Downstream effect
Weight loss via appetite suppression (GLP-1 axis) and increased energy expenditure (glucagon axis); improved glycemic control in T2D
Activated Wnt/β-catenin signaling promotes hair follicle regeneration, dermal stem cell activation, reduced myofibroblast differentiation
Feedback intact?
Yes — physiological receptor-mediated signaling preserved
Not applicable — pathway derepression rather than receptor agonism
Origin
Synthetic oxyntomodulin analogue — endogenous peptide with dual GLP-1/glucagon activity
Engineered fusion: cell-penetrating PTD sequence + Dvl-binding motif targeting CXXC5
Antibody development
—
—
02Dosage Protocols
Parameter
Mazdutide
PTD-DBM
Phase 2 studied dose
—
Dose escalation
3 mg → 6 mg → 9 mg (titration schedule in trials)
Gradual escalation to minimize GI side effects.
—
Duration (trials)
24–48 weeks
—
Population
Non-diabetic adults BMI ≥30 kg/m² or ≥27 kg/m² with comorbidities
—
Wound healing protocol
—
Hydrogel patch delivery (concentration not disclosed)
Pyrogallol-HA patch, murine model.
Hair regeneration protocol
—
Topical application (exact dose not disclosed)
Wound-induced hair neogenesis model, mice.
Co-administration
—
Valproic acid (GSK-3β inhibitor) for wound healing synergyLee 2023
Combined treatment maximized scar reduction.
Human translation
—
No published human studies
03Metabolic / Fat Loss Evidence
Parameter
Mazdutide
PTD-DBM
Percentage body weight loss
12.4% (pooled meta-analysis, 9 mg dose)
95% CI: -16.15% to -8.68%, random-effects model.Azam 2026
—
Responder rate (≥10% loss)
Not explicitly reported in available abstracts
—
Visceral fat
Expected benefit from glucagon-mediated lipolysis (not quantified in abstracts)
—
Glycemic improvement
HbA1c reduction in T2D cohort (Phase 3 DREAMS-3)
—
Key publications
Ji et al. Med 2026 · Azam et al. Diab Obes Metab 2026 · Luo et al. Contemp Clin Trials 2026
—
04Side Effects & Safety
Parameter
Mazdutide
PTD-DBM
Gastrointestinal symptoms
Nausea, vomiting, diarrhea (most common, GLP-1 effect)
—
Injection site reactions
Erythema, pruritus, local discomfort
—
Hypoglycemia
Low risk in non-diabetic cohort; monitor in T2D with insulin or sulfonylureas
—
Cardiovascular effects
Increased heart rate (glucagon effect, transient)
—
Pancreatitis risk
Theoretical (incretin class effect); monitor amylase/lipase if abdominal pain
—
Thyroid C-cell tumors
Black box warning for GLP-1 class (rodent data); human relevance unclear
—
Gallbladder disease
Cholelithiasis, cholecystitis (rapid weight loss effect)
—
Tolerability
Generally well-tolerated; GI effects diminish with dose titration
—
Reported adverse events
—
None reported in animal studies
Wnt pathway activation risks
—
Theoretical risk of aberrant proliferation; Wnt dysregulation linked to tumorigenesis
Long-term safety
—
Unknown — no chronic dosing or human data
Delivery vehicle effects
—
HA-PG hydrogel well-tolerated in mice; human translation pending
Absolute Contraindications
Mazdutide
- ·Personal or family history of medullary thyroid carcinoma
- ·Multiple endocrine neoplasia syndrome type 2 (MEN 2)
- ·Hypersensitivity to mazdutide or excipients
- ·Pregnancy
PTD-DBM
- ·Active malignancy (Wnt pathway involvement in tumorigenesis)
- ·Pregnancy / lactation (no safety data)
Relative Contraindications
Mazdutide
- ·History of pancreatitis
- ·Severe gastroparesis or GI motility disorders
- ·Diabetic retinopathy (monitor, risk of worsening with rapid glycemic change)
- ·Renal impairment (limited data, use with caution)
PTD-DBM
- ·History of Wnt-driven tumors
- ·Skin lesions with uncertain malignant potential
05Administration Protocol
Parameter
Mazdutide
PTD-DBM
1. Preparation
Supplied as pre-filled pen or reconstituted vial (per manufacturer instructions). Inspect solution — should be clear, colorless to pale yellow. Discard if cloudy or particulate matter present.
Pyrogallol-functionalized hyaluronic acid (HA-PG) hydrogel patch loaded with PTD-DBM peptide, applied directly to wound bed. Adhesive hydrogel provides sustained release over multiple days.Lee 2023
2. Injection site
Subcutaneous — abdomen preferred, also thigh or upper arm. Rotate sites weekly. Avoid areas with scarring, moles, or active inflammation.
Topical application to scalp or wound site. Precise formulation not disclosed; studies used Cxxc5 knockout or direct peptide application in wound-induced hair neogenesis models.Ryu 2023
3. Timing
Once weekly, same day each week. May be taken with or without food. If dose missed, administer within 3 days; if >3 days, skip and resume next scheduled dose.
PTD-DBM + valproic acid (GSK-3β inhibitor) in HA-PG patch showed synergistic effect on scar reduction and regenerative wound healing. VPA enhances Wnt pathway activation downstream.Lee 2023
4. Storage
Refrigerate 2–8 °C. Do not freeze. May be kept at room temperature (<25 °C) for up to 14 days if needed. Protect from light.
Not disclosed in available literature. Peptide stability and storage conditions not published.
5. Needle technique
Use supplied needle or compatible insulin syringe (if reconstituting). Pinch skin, inject at 90° angle. Hold 5–10 seconds before withdrawing needle to prevent leakage.
—